MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
Top Cited Papers
Open Access
- 1 September 2016
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 22 (13), 1719-1731
- https://doi.org/10.1177/1352458516667568
Abstract
Background: Treatment with MD1003 (high-dose biotin) showed promising results in progressive multiple sclerosis (MS) in a pilot open-label study. Objective: To confirm the efficacy and safety of MD1003 in progressive MS in a double-blind, placebo-controlled study. Methods: Patients ( n = 154) with a baseline Expanded Disability Status Scale (EDSS) score of 4.5–7 and evidence of disease worsening within the previous 2 years were randomised to 12-month MD1003 (100 mg biotin) or placebo thrice daily, followed by 12-month MD1003 for all patients. The primary endpoint was the proportion of patients with disability reversal at month 9, confirmed at month 12, defined as an EDSS decrease of ⩾1 point (⩾0.5 for EDSS 6–7) or a ⩾20% decrease in timed 25-foot walk time compared with the best baseline among screening or randomisation visits. Results: A total of 13 (12.6%) MD1003-treated patients achieved the primary endpoint versus none of the placebo-treated patients ( p = 0.005). MD1003 treatment also reduced EDSS progression and improved clinical impression of change compared with placebo. Efficacy was maintained over follow-up, and the safety profile of MD1003 was similar to that of placebo. Conclusion: MD1003 achieves sustained reversal of MS-related disability in a subset of patients with progressive MS and is well tolerated.Keywords
This publication has 25 references indexed in Scilit:
- Positive and negative interference in immunoassays following biotin ingestion: a pharmacokinetic studyPathology, 2012
- Will the real multiple sclerosis please stand up?Nature Reviews Neuroscience, 2012
- A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MSNeurology, 2011
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trialAnnals of Neurology, 2009
- Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trialAnnals of Neurology, 2007
- Interferon beta-1b in secondary progressive MSNeurology, 2004
- Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Benefit of interferon β-1a on MSFC progression in secondary progressive MSNeurology, 2002
- Relapses and Progression of Disability in Multiple SclerosisThe New England Journal of Medicine, 2000
- Cladribine and progressive MSNeurology, 2000